In The News Posted February 22, 2020 Share Posted February 22, 2020 INDIANAPOLIS, Feb. 21, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trulicity® (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.